메뉴 건너뛰기




Volumn 88, Issue 8, 2003, Pages 888-894

Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas

Author keywords

Aggressive non Hodgkin's lymphoma; Anthracenedione; Anthracycline; BBR 2278; Phase II study

Indexed keywords

ANTHRACYCLINE; ANTHRAQUINONE DERIVATIVE; AZAANTHRACENEDIONE; UNCLASSIFIED DRUG;

EID: 0141649441     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (48)

References (32)
  • 1
    • 0030444894 scopus 로고    scopus 로고
    • A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy
    • Abraham R, Basser RL, Green MD. A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy. Drug Saf 1996;15:406-29.
    • (1996) Drug Saf , vol.15 , pp. 406-429
    • Abraham, R.1    Basser, R.L.2    Green, M.D.3
  • 2
    • 0027343763 scopus 로고
    • Strategies for prevention of anthracycline cardiotoxicity
    • Basser RL, Green MD. Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Rev 1993;19:57-77.
    • (1993) Cancer Treat Rev , vol.19 , pp. 57-77
    • Basser, R.L.1    Green, M.D.2
  • 3
    • 0032563825 scopus 로고    scopus 로고
    • Current concepts: Doxorubicin induced cardiomyopathies
    • Singal PK, Iliskovic N. Current concepts: doxorubicin induced cardiomyopathies. N Engl J Med 1998;339:900-5
    • (1998) N Engl J Med , vol.339 , pp. 900-905
    • Singal, P.K.1    Iliskovic, N.2
  • 4
    • 0025059659 scopus 로고
    • Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: Relationship with binding mode and anti-tumour activity
    • Denny WA, Wakelin LP. Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: relationship with binding mode and anti-tumour activity. Anticancer Drug Des 1990;5:189-200.
    • (1990) Anticancer Drug Des , vol.5 , pp. 189-200
    • Denny, W.A.1    Wakelin, L.P.2
  • 5
    • 0022340391 scopus 로고
    • Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids
    • Lown JW, Morgan AR, Yen SF, Wang YH, Wilson WD. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry 1985;24:4028-35.
    • (1985) Biochemistry , vol.24 , pp. 4028-4035
    • Lown, J.W.1    Morgan, A.R.2    Yen, S.F.3    Wang, Y.H.4    Wilson, W.D.5
  • 6
    • 0028822554 scopus 로고
    • Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells
    • Hazlehurst LA, Krapcho AP, Hacker MP. Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. Biochem Pharmacol 1995;50:1087-94.
    • (1995) Biochem Pharmacol , vol.50 , pp. 1087-1094
    • Hazlehurst, L.A.1    Krapcho, A.P.2    Hacker, M.P.3
  • 7
    • 0031012073 scopus 로고    scopus 로고
    • Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones
    • de Isabella P, Palumbo M, Sissi C, Carenini N, Capranico G, Menta E, et al. Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones. Biochem Pharmacol 1997;53:161-9.
    • (1997) Biochem Pharmacol , vol.53 , pp. 161-169
    • De Isabella, P.1    Palumbo, M.2    Sissi, C.3    Carenini, N.4    Capranico, G.5    Menta, E.6
  • 8
    • 0035746666 scopus 로고    scopus 로고
    • BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity
    • Beggiolin G, Crippa L, Menta E, Manzotti C, Cavalletti E, Pezzoni G, et al. BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 2001;87:407-16.
    • (2001) Tumori , vol.87 , pp. 407-416
    • Beggiolin, G.1    Crippa, L.2    Menta, E.3    Manzotti, C.4    Cavalletti, E.5    Pezzoni, G.6
  • 9
    • 0018566889 scopus 로고
    • Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse
    • Bertazzoli C, Bellini O, Magrini U, Tosana MG. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat Rep 1979;63:1877-83.
    • (1979) Cancer Treat Rep , vol.63 , pp. 1877-1883
    • Bertazzoli, C.1    Bellini, O.2    Magrini, U.3    Tosana, M.G.4
  • 10
    • 0034988022 scopus 로고    scopus 로고
    • Phase I study of BBR 2778, a new aza-anthracenedione in advanced or refractory non-Hodgkin's lymphoma
    • Borchmann P, Schnell R, Knippertz R, Staak JO, Camboni GM, Bernareggi A, et al. Phase I study of BBR 2778, a new aza-anthracenedione in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 2001;12:661-7.
    • (2001) Ann Oncol , vol.12 , pp. 661-667
    • Borchmann, P.1    Schnell, R.2    Knippertz, R.3    Staak, J.O.4    Camboni, G.M.5    Bernareggi, A.6
  • 11
    • 0035136099 scopus 로고    scopus 로고
    • A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies
    • Faivre S, Raymond E, Boige V, Gatineau M, Buthaut X, Rixe O, et al. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin Cancer Res 2001;7:43-50.
    • (2001) Clin Cancer Res , vol.7 , pp. 43-50
    • Faivre, S.1    Raymond, E.2    Boige, V.3    Gatineau, M.4    Buthaut, X.5    Rixe, O.6
  • 12
    • 0033711725 scopus 로고    scopus 로고
    • A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly
    • Dawson LK, Jodrell DI, Bowman A, Rye R, Byrne B, Bernareggi A, et al. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur J Cancer 2000;36:2353-9.
    • (2000) Eur J Cancer , vol.36 , pp. 2353-2359
    • Dawson, L.K.1    Jodrell, D.I.2    Bowman, A.3    Rye, R.4    Byrne, B.5    Bernareggi, A.6
  • 13
    • 0032784783 scopus 로고    scopus 로고
    • World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Air-lie House, Virginia, November 1997
    • Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Air-lie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
    • (1999) J Clin Oncol , vol.17 , pp. 3835-3849
    • Harris, N.L.1    Jaffe, E.S.2    Diebold, J.3    Flandrin, G.4    Muller-Hermelink, H.K.5    Vardiman, J.6
  • 14
    • 0030883053 scopus 로고    scopus 로고
    • 1997 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
    • American Society of Clinical Oncology
    • 1997 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1997;15:3288.
    • (1997) J Clin Oncol , vol.15 , pp. 3288
  • 15
    • 0002207395 scopus 로고
    • Grading of toxicity
    • Macdonald JHD, Mayer R, eds. Philadelphia, PA, USA. Lippincott
    • Macdonald J, Haller D, Mayer R. Grading of toxicity. In: Macdonald JHD, Mayer R, eds. Manual of Oncologic Therapeutics. Philadelphia, PA, USA. Lippincott, 1995.
    • (1995) Manual of Oncologic Therapeutics
    • Macdonald, J.1    Haller, D.2    Mayer, R.3
  • 16
    • 0042449063 scopus 로고    scopus 로고
    • Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
    • NCI Sponsored International Working Group
    • Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
    • (1999) J Clin Oncol , vol.17 , pp. 1244
    • Cheson, B.D.1    Horning, S.J.2    Coiffier, B.3    Shipp, M.A.4    Fisher, R.I.5    Connors, J.M.6
  • 17
    • 0026763215 scopus 로고
    • Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma
    • De Lord C, Newland AC, Linch DC, Vaughan Hudson B, Vaughan Hudson G. Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma. Hematol Oncol 1992;10:81-6.
    • (1992) Hematol Oncol , vol.10 , pp. 81-86
    • De Lord, C.1    Newland, A.C.2    Linch, D.C.3    Vaughan Hudson, B.4    Vaughan Hudson, G.5
  • 18
    • 0019997890 scopus 로고
    • IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy
    • Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982;60:693-7.
    • (1982) Blood , vol.60 , pp. 693-697
    • Cabanillas, F.1    Hagemeister, F.B.2    Bodey, G.P.3    Freireich, E.J.4
  • 19
    • 0019813624 scopus 로고
    • Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B
    • Cavalli F, Jungi WF, Nissen NI, Pajak TF, Coleman M, Holland JF. Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B. Cancer 1981;48:1927-30.
    • (1981) Cancer , vol.48 , pp. 1927-1930
    • Cavalli, F.1    Jungi, W.F.2    Nissen, N.I.3    Pajak, T.F.4    Coleman, M.5    Holland, J.F.6
  • 20
    • 12944259223 scopus 로고    scopus 로고
    • Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas
    • Groupe d'Etude des Lymphomes de I'Adulte
    • Casasnovas RO, Haioun C, Dumontet C, Gabarre J, Richard B, Lederlin P, et al. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de I'Adulte. Haematologica 2000;85:502-7.
    • (2000) Haematologica , vol.85 , pp. 502-507
    • Casasnovas, R.O.1    Haioun, C.2    Dumontet, C.3    Gabarre, J.4    Richard, B.5    Lederlin, P.6
  • 21
    • 0032784782 scopus 로고    scopus 로고
    • Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
    • Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3786-92.
    • (1999) J Clin Oncol , vol.17 , pp. 3786-3792
    • Fossa, A.1    Santoro, A.2    Hiddemann, W.3    Truemper, L.4    Niederle, N.5    Buksmaui, S.6
  • 22
    • 0025970652 scopus 로고
    • The evolving role of etoposide in the management of lymphomas and Hodgkin's disease
    • O'Reilly SE, Klimo P, Connors JM. The evolving role of etoposide in the management of lymphomas and Hodgkin's disease. Cancer 1991;67:271-80.
    • (1991) Cancer , vol.67 , pp. 271-280
    • O'Reilly, S.E.1    Klimo, P.2    Connors, J.M.3
  • 23
    • 0027369897 scopus 로고
    • Pilot study and randomised trial of mitozantrone and ifosfamide for relapsed non-Hodgkin's lymphoma
    • Scotland and Newcastle Lymphoma group (SNLG) Working Party on Therapy
    • Prescott RJ, Leonard RC. Pilot study and randomised trial of mitozantrone and ifosfamide for relapsed non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma group (SNLG) Working Party on Therapy. Leuk Lymphoma 1993; 11:111-4.
    • (1993) Leuk Lymphoma , vol.11 , pp. 111-114
    • Prescott, R.J.1    Leonard, R.C.2
  • 24
    • 0031891979 scopus 로고    scopus 로고
    • Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246
    • Press OW, LeBlanc M, O'Rourke TJ, Gagnet S, Chapman RA, Balcerzak SP, et al. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. J Clin Oncol 1998; 16:574-8,
    • (1998) J Clin Oncol , vol.16 , pp. 574-578
    • Press, O.W.1    LeBlanc, M.2    O'Rourke, T.J.3    Gagnet, S.4    Chapman, R.A.5    Balcerzak, S.P.6
  • 25
    • 0035008043 scopus 로고    scopus 로고
    • Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma
    • Tulpule A, Rarick MU, Kolitz J, Bernstein J, Myers A, Buchanan LA, et al. Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann Oncol 2001;12:457-62.
    • (2001) Ann Oncol , vol.12 , pp. 457-462
    • Tulpule, A.1    Rarick, M.U.2    Kolitz, J.3    Bernstein, J.4    Myers, A.5    Buchanan, L.A.6
  • 26
    • 0035986759 scopus 로고    scopus 로고
    • Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: Results from a prospective phase II study
    • Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP, et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica 2002; 87:822-7.
    • (2002) Haematologica , vol.87 , pp. 822-827
    • Martino, R.1    Perea, G.2    Caballero, M.D.3    Mateos, M.V.4    Ribera, J.M.5    De Oteyza, J.P.6
  • 27
    • 0032409240 scopus 로고    scopus 로고
    • DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide: An effective and well-tolerated new regimen for patients with relapsed lymphoma
    • Reiser M, Schnell R, Straub G, Borchmann P, Wilhelm M, Ubelacker R, et al. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide: an effective and well-tolerated new regimen for patients with relapsed lymphoma. Leuk Lymphoma 1998;31:359-66.
    • (1998) Leuk Lymphoma , vol.31 , pp. 359-366
    • Reiser, M.1    Schnell, R.2    Straub, G.3    Borchmann, P.4    Wilhelm, M.5    Ubelacker, R.6
  • 28
    • 0025957150 scopus 로고
    • PARMA international protocol: Pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients)
    • Philip T, Chauvin F, Bron D, Guglielmi C, Hagenbeek A, Coiffier B, et al. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). Ann Oncol 1991;2 Suppl 1:57-64.
    • (1991) Ann Oncol , vol.2 , Issue.SUPPL. 1 , pp. 57-64
    • Philip, T.1    Chauvin, F.2    Bron, D.3    Guglielmi, C.4    Hagenbeek, A.5    Coiffier, B.6
  • 29
    • 0034329772 scopus 로고    scopus 로고
    • Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH
    • Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000;18:3633-42.
    • (2000) J Clin Oncol , vol.18 , pp. 3633-3642
    • Gutierrez, M.1    Chabner, B.A.2    Pearson, D.3    Steinberg, S.M.4    Jaffe, E.S.5    Cheson, B.D.6
  • 30
  • 31
    • 0029767924 scopus 로고    scopus 로고
    • Mitoxantrone: A review of its pharmacological properties and use in acute nonlymphoblastic leukaemia
    • Dunn CJ, Goa KL. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Drugs Aging 1996;9:122-47.
    • (1996) Drugs Aging , vol.9 , pp. 122-147
    • Dunn, C.J.1    Goa, K.L.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.